KRAS mutation is among the most prominent molecular markers in metastatic CRC patients, and mutations of KRAS render cells responsive to anti-cancer therapy such as anti-EGFR antibody treatment [73]. This evidence concerns the gene KRAS and colorectal carcinoma.